Conavi Medical Corp. (CNVIF)
| Market Cap | 22.77M |
| Revenue (ttm) | 1.60M |
| Net Income (ttm) | -32.28M |
| Shares Out | n/a |
| EPS (ttm) | -5.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8 |
| Average Volume | 14,109 |
| Open | 0.2114 |
| Previous Close | 0.2580 |
| Day's Range | 0.2114 - 0.2114 |
| 52-Week Range | 0.0007 - 1.0000 |
| Beta | n/a |
| RSI | 43.62 |
| Earnings Date | Mar 7, 2025 |
About Conavi Medical
Conavi Medical Corp. focuses on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. It offers Novasight Hybrid System, a system that combines intravascular ultrasound and optical coherence tomography to enable simultaneous and co-registered imaging of coronary arteries. The company is based in Toronto, Canada. [Read more]
Financial Performance
In 2024, Conavi Medical's revenue was 2.16 million, a decrease of -8.59% compared to the previous year's 2.36 million. Losses were -43.62 million, 67.2% more than in 2023.
Financial numbers in CAD Financial StatementsNews
Conavi Medical's Novasight Hybrid™ System Named “Product Innovation of the Year” at 2025 Minnesota Manufacturing Awards
Award recognizes Novasight Hybrid™ System's significant advance in intracoronary imaging technology Award recognizes Novasight Hybrid™ System's significant advance in intracoronary imaging technology
Conavi Medical to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 25, 2025) - Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ("Conavi" or the "Company"), a commercial stage medical device company focused on designing, manu...
CPOINT Capital Corp. Announces Changes to Holdings in Conavi Medical Corp.
TORONTO, April 25, 2025 (GLOBE NEWSWIRE) -- CPOINT Capital Corp. (“CPOINT”) announces that, on April 23, 2025, it and its affiliate Juno Pharmaceuticals LP (“Juno”) acquired 1,875,000 common shares (t...
Conavi Medical Corp. Announces Closing of $20M Public Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi” or the “Co...
Conavi Medical Announces Results From Its Annual General Meeting of Shareholders and Adoption of Amendments to Omnibus Equity Incentive Plan
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufac...
Conavi Medical Corp. Announces Upsize to its Previously Announced Public Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi” or the “C...
Conavi Medical Announces Uplisting to OTCQB Venture Market
- E xpected to enhance visibility and access to U.S. investors
Conavi Medical Highly Encouraged by New U.S. Intracoronary Guidelines
– IVUS and OCT cited as playing essential and complementary roles, validating Novasight's unique hybrid imaging capability – Guidelines constitute strong recommendations based on the highest level of ...
Conavi Medical Retains BND Projects Inc. for Corporate Development Services
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a commercial stage medical device company focused on designing, manufacturing, and marketi...
Conavi Medical Corp. Announces Proposed Public Offering of Units
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi M...